Literature DB >> 8961277

Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.

K Sharma1, Y C Patel, C B Srikant.   

Abstract

Somatostatin (SST) exerts direct antiproliferative effects in tumor cells, triggering either growth arrest or apoptosis. The cellular actions of SST are transduced through a family of five distinct somatostatin receptor subtypes (SSTR1-5). Whereas growth inhibition has been reported to follow stimulation of protein tyrosine phosphatase via SSTR2 or inhibition of Ca2+ channels via SSTR5 in heterologous expression systems, the subtype selectivity for signaling apoptosis has not been investigated. The tumor suppressor protein p53 and the protooncogene product c-Myc regulate cell cycle progression (growth factors present) or apoptosis (growth factors absent). The p53-induced G1 arrest requires induction of p21, an inhibitor of cyclin-dependent kinases, whereas apoptosis requires induction of Bax. c-Myc is capable of abrogating p53-induced G1 arrest by interfering with the inhibitory action of p21 on cyclin-dependent kinases. We have, therefore, investigated the regulation of p53, p21, c-Myc, and Bax and cellular apoptosis in relation to cell cycle progression in CHO-K1 cells stably expressing individual human SSTR1-5. We demonstrate that apoptosis is signaled uniquely through human SSTR3 and is associated with dephosphorylation-dependent conformational change in wild-type (wt) p53 as well as induction of Bax. The induction of wt p53 occurs rapidly and precedes the onset of apoptosis. We show that the increase in wt p53 is not associated with the induction of p21 or c-Myc when octreotide-induced apoptosis becomes evident, suggesting that such apoptosis does not require G1 arrest and is not c-Myc dependent. These findings provide the first evidence for hormonal induction of wt p53-associated apoptosis via G protein-coupled receptor in a subtype-selective manner.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961277     DOI: 10.1210/mend.10.12.8961277

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  56 in total

1.  SST3-selective potent peptidic somatostatin receptor antagonists.

Authors:  J C Reubi; J C Schaer; S Wenger; C Hoeger; J Erchegyi; B Waser; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

Authors:  David L Kleinberg; Pietro Ameri; Baljit Singh
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

3.  Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.

Authors:  A P Casarini; E M Pinto; R S Jallad; R R Giorgi; D Giannella-Neto; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

4.  Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.

Authors:  Paola Sartori; Chiara Mussi; Carlo Angelini; Stefano Crippa; Roberto Caprotti; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2005-06-21       Impact factor: 3.445

Review 5.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

6.  Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.

Authors:  B Mariniello; I Finco; P Sartorato; A Patalano; M Iacobone; V Guzzardo; A Fassina; F Mantero
Journal:  J Endocrinol Invest       Date:  2010-10-27       Impact factor: 4.256

Review 7.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

8.  Somatostatin and cancer: applying endocrinology to oncology.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2004-08-23       Impact factor: 4.742

9.  Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Authors:  H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 10.  Future treatment strategies of aggressive pituitary tumors.

Authors:  Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.